Rotavirus vaccine – along with our team – demonstrates efficacy in Indian clinical study

Rotavirus vaccine – along with our team – demonstrates efficacy in Indian clinical study hrandall Tue, 09/26/2017 – 11:13 Sep 26, 2017 Tushar Tewari Senior Medical Officer, CVIA Clinical, and PATH’s Team Leader for the BRV-PV Phase 3 efficacy study As results from a Phase 3 efficacy study in India of the Serum Institute of India Pvt. Ltd. (SIIPL)’s rotavirus vaccine BRV-PV (now known as ROTASIIL) are published in the journal Vaccine, I find myself reflecting on the great partnership that conducted the trial. The Serum Institute and PATH worked with six strong community-based clinical sites, all supported by the Clinical Research Organization, DiagnoSearch. 

Follow this link:  

Rotavirus vaccine – along with our team – demonstrates efficacy in Indian clinical study